Background The clinical trial safety database for tiotropium has been augmented with a 4-year
trial in patients with COPD, which provides an opportunity to better evaluate the …

Introduction Chronic obstructive pulmonary disease (COPD) exacerbations are associated
with systemic consequences. Data from a 4-year trial (Understanding Potential Long-term …

Background The 2013 GOLD classification system for COPD distinguishes four stages: A (low
symptoms, low exacerbation risk), B (high symptoms, low risk), C (low symptoms, high risk) …

Background Tiotropium is a long-acting inhaled anticholinergic developed for the treatment
of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We …

Background Tiotropium is an anticholinergic bronchodilator for symptom relief and reducing
exacerbations with an established safety profile in patients with chronic obstructive …

INTRODUCTION: In chronic diseases such as chronic obstructive pulmonary disease (COPD),
patients may not perceive all of the benefits of drug therapy until withdrawal. Thus, we …

Sparse information exists about chronic obstructive pulmonary disease (COPD) outcomes
among different ethnic groups. To determine whether the effect of tiotropium on COPD …

A retrospective analysis of the Understanding Potential Long-term Impacts on Function with
Tiotropium (UPLIFT®) trial data was performed, grading patients by the 2013 Global initiative …

Background Data have highlighted the potential bias introduced by withdrawal of inhaled
corticosteroids at randomization in chronic obstructive pulmonary disease trials examining …

Background Exacerbations are a defining outcome of chronic obstructive pulmonary
disease (COPD). We evaluated the effect of tiotropium on COPD exacerbations and related …